The Quality of Antimalarials - A Study in Selected African Countries - EDM Research Series No. 030
(2003; 67 pages) View the PDF document
Table of Contents
View the documentAuthors
View the documentCountry Research Team Leaders
View the documentLaboratory Support
View the documentAcknowledgements
View the documentAcronyms
View the documentExecutive summary
View the document1. Background
Open this folder and view contents2. Methodology
View the document3. Results
Close this folder4. Discussion
View the document4.1 Is there a problem?
View the document4.2 What is the magnitude of the problem?
View the document4.3 Is the problem limited to a particular distribution level?
View the document4.4 Is the problem limited to imported or domestic products?
View the document4.5 Limitations of the methodology
Open this folder and view contents5. Conclusions and recommendations
View the documentReferences
Open this folder and view contentsTables
Open this folder and view contentsAnnexes
View the documentOther documents in the EDM Research Series
View the documentEDM Research Series No. 30

4.2 What is the magnitude of the problem?

The data presented in this report indicate that there is a significant problem of substandard antimalarial drug products circulating in the markets of the participating countries. The most significant results were the low content failures for CQT (ranging from a low of 5.2% in Sudan to a high of 66.7% in Ghana) and SPT dissolution (ranging from a low of 75% in Ghana to 100% for Mali, Mozambique and Zimbabwe). However, as this study faced a number of logistical problems, i.e. sample containers, sample quantities, labelling and coding, these results can only be taken as indicative, but not conclusive.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018